Journal of Surgery Concepts & Practice >

2022 , Vol. 27 >Issue 03: 271 - 275

DOI: https://doi.org/10.16139/j.1007-9610.2022.03.018

Review

Progress of study on medullary thyroid carcinoma with serum calcitonin-negative and large mass

Expand
  • Department of Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2021-08-12

  Online published: 2022-08-03

Fold

Abstract

The characteristics of medullary thyroid carcinoma (MTC) include strong invasiveness, early lymph node metastasis and distant metastasis. MTC is aggresive only less than anaplastic carcinoma in all thyroid malignancies. Serum calcitonin is the most sensitive tumor marker for detecting MTC, which correlates with tumor size. However, it is difficult to diagnose some MTC patients with tumor diameter greater than 1 cm and serum calcitonin negative. This review focuses on recent advances in study on MTC with diameter greater than 1 cm and serum calcitonin negative.

Key words： Medullary thyroid carcinoma; Calcitonin; Prediction

Cite this article

LI Rui, LIU Zhuoran, YAN Jiqi . Progress of study on medullary thyroid carcinoma with serum calcitonin-negative and large mass[J]. Journal of Surgery Concepts & Practice, 2022 , 27(03) : 271 -275 . DOI: 10.16139/j.1007-9610.2022.03.018

References

[1] Viola D, Elisei R. Management of medullary thyroid cancer[J]. Endocrinol Metab Clin North Am, 2019, 48(1):285-301.
[2] Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma[J]. Thyroid, 2015, 25(6):567-610.
[3] Ceolin L, Duval MADS, Benini AF, et al. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives[J]. Endocr Relat Cancer, 2019, 26(9):R499-R518.
[4] Samà MT, Rossetto Giaccherino R, Gallo M, et al. Clinical challenges with calcitonin-negative medullary thyroid carcinoma[J]. J Cancer Res Clin Oncol, 2016, 142(9):2023-2029.
[5] Liu Y, Yuan L, Yang D, et al. Serum calcitonin negative mixed medullary-follicular carcinoma initially diagnosed as medullary thyroid carcinoma by fine-needle aspiration cytology: a case report and review of the literatures[J]. Diagn Cytopathol, 2018, 46(8):690-693.
[6] Kartal Baykan E, Erdoan M. Basal and pentagastrin-stimulated calcitonin cut-off values in diagnosis of preoperative medullary thyroid cancer[J]. Turk J Med Sci, 2021, 51(2):650-656.
[7] Filimon S, Payne RJ, Black MJ, et al. Calcitonin secretory index and unsuspected nodal disease in medullary thyroid carcinoma[J]. Endocr Pract, 2018, 24(5):460-467.
[8] 王宇, 田文, 嵇庆海, 等. 甲状腺髓样癌诊断与治疗中国专家共识(2020版)[J]. 中国实用外科杂志, 2020, 40(9):1012-1020.
[9] Haddad RI, Nasr C, Bischoff L, et al. NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018[J]. J Natl Compr Canc Netw, 2018, 16(12):1429-1440.
[10] Allelein S, Ehlers M, Morneau C, et al. Measurement of basal serum calcitonin for the diagnosis of medullary thyroid cancer[J]. Horm Metab Res, 2018, 50(1):23-28.
[11] Sobol RE, Memoli V, Deftos LJ. Hormone-negative, chromogranin A-positive endocrine tumors[J]. N Engl J Med, 1989, 320(7):444-447.
[12] Redding AH, Levine SN, Fowler MR. Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses[J]. Thyroid, 2000, 10(10):919-922.
[13] Bockhorn M, Frilling A, Rewerk S, et al. Lack of eleva-ted serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma[J]. Thyroid, 2004, 14(6):468-470.
[14] Sand M, Gelos M, Sand D, et al. Serum calcitonin negative medullary thyroid carcinoma[J]. World J Surg Oncol, 2006, 4:97.
[15] Giovanella L, Crippa S, Cariani L. Serum calcitonin-negative medullary thyroid carcinoma: role of CgA and CEA as complementary markers[J]. Int J Biol Markers, 2008, 23(2):129-131.
[16] Dora JM, Canalli MH, Capp C, et al. Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature[J]. Thyroid, 2008, 18(8):895-899.
[17] Alapat DV, Ain KB, Sloan DA, et al. Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma[J]. Endocrine, 2011, 39(2):148-152.
[18] Frank-Raue K, Machens A, Leidig-Bruckner G, et al. Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma[J]. Thyroid, 2013, 23(3):294-300.
[19] Brutsaert EF, Gersten AJ, Tassler AB, et al. Medullary thyroid cancer with undetectable serum calcitonin[J]. J Clin Endocrinol Metab, 2015, 100(2):337-341.
[20] Zhou Q, Yue S, Cheng Y, et al. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin[J]. Exp Toxicol Pathol, 2017, 69(8):575-579.
[21] Cipri C, Vescini F, Torresan F, et al. An unusual case of medullary thyroid carcinoma and a revision of current li-terature[J]. Endocr Metab Immune Disord Drug Targets, 2019, 19(2):226-229.
[22] Murphy DC, Johnson SJ, Aspinall S. Calcitonin-negative medullary thyroid carcinoma: the “triple-negative” pheno-type[J]. Ann R Coll Surg Engl, 2020, 102(3):e63-e66.
[23] Jingzhu Z, Xiangqian Z, Ming G, et al. Clinical challenges with calcitonin-negative medullary thyroid carcinoma: three case reports and a review of the literature[J]. Ann R Coll Surg Engl, 2022, 104(3):221-230.
[24] Kim SJ, Yun HJ, Shin SJ, et al. Serum calcitonin-negative medullary thyroid carcinoma: a case series of 19 patients in a single center[J]. Front Endocrinol (Lausanne), 2021, 12:747704.
[25] Montgomery G, Collins L, Coghlin C, et al. Calcitonin negative medullary thyroid cancer in ectopic thyroid tissue: a rare diagnosis in an unusual location[J]. BMJ Case Rep, 2020, 13(8):e236865.
[26] Leboeuf R, Langlois MF, Martin M, et al. “Hook effect” in calcitonin immunoradiometric assay in patients with metastatic medullary thyroid carcinoma: case report and review of the literature[J]. J Clin Endocrinol Metab, 2006, 91(2):361-364.
[27] Fernández-Ferreira R, De la Peña-López IR, Zamudio-Coronado KW, et al. Calcitonin-negative neuroendocrine carcinoma of the thyroid gland: case report and literature review[J]. Case Rep Oncol, 2021, 14(1):112-122.
[28] Leboulleux S, Baudin E, Young J, et al. Gastroenteropancreatic neuroendocrine tumor metastases to the thyroid gland: differential diagnosis with medullary thyroid carcinoma[J]. Eur J Endocrinol, 1999, 140(3):187-191.
[29] Konstantinidis A, Stang M, Roman SA, et al. Surgical management of medullary thyroid carcinoma[J]. Updates Surg, 2017, 69(2):151-160.
[30] Hassan A, Siddique M, Riaz S, et al. Medullary thyroid carcinoma: prognostic variables and tumour markers affecting survival[J]. J Ayub Med Coll Abbottabad, 2018, 30(4):S627-S632.
[31] Parmer M, Milan S, Torabi A. Calcitonin-negative neuroendocrine tumor of the thyroid[J]. Int J Surg Pathol, 2017, 25(2):191-194.
[32] Giovanella L, Garo ML, Ceriani L, et al. Procalcitonin as an alternative tumor marker of medullary thyroid carcinoma[J]. J Clin Endocrinol Metab, 2021, 106(12):3634-3643.
[33] Karagiannis AK, Girio-Fragkoulakis C, Nakouti T. Procalcitonin: a new biomarker for medullary thyroid cancer? a systematic review[J]. Anticancer Res, 2016, 36(8):3803-3810.
[34] Vargas CVF, Ceolin L, Scheffel RS, et al. The tissue expression pattern of CA 19.9 is associated with oncological features in medullary thyroid carcinoma[J]. Endocrine, 2020, 70(3):544-551.
[35] Elisei R, Lorusso L, Piaggi P, et al. Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer[J]. Eur J Endocrinol, 2015, 173(3):297-304.
[36] Liu MJ, Liu ZF, Hou YY, et al. Ultrasonographic characteristics of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma[J]. Oncotarget, 2017, 8(16):27520-27528.
[37] Tripathy S, Aggrawal S, Subudhi K, et al. Calcitonin-negative neuroendocrine tumor of the thyroid on 68Ga DOTANOC PET-CT[J]. Clin Nucl Med, 2019, 44(9):e546-e547.
[38] Naswa N, Sharma P, Suman Kc S, et al. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT[J]. Nucl Med Commun, 2012, 33(7):766-774.
[39] Trimboli P, Giovanella L, Crescenzi A, et al. Medullary thyroid cancer diagnosis: an appraisal[J]. Head Neck, 2014, 36(8):1216-1223.
[40] Trimboli P, Cremonini N, Ceriani L, et al. Calcitonin measurement in aspiration needle washout fluids has higher sensitivity than cytology in detecting medullary thyroid cancer: a retrospective multicentre study[J]. Clin Endocrinol (Oxf), 2014, 80(1):135-140.
[41] Salvatore D, Santoro M, Schlumberger M. The importance of the RET gene in thyroid cancer and therapeutic implications[J]. Nat Rev Endocrinol, 2021, 17(5):296-306.
[42] Thomas CM, Asa SL, Ezzat S, et al. Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines[J]. Curr Oncol, 2019, 26(5):338-344.
Options
Outlines

/

〈 〉